APA

Marks W. J., Ostrem J. L., Verhagen L., Starr P. A., Larson P. S., Bakay R. A., Taylor R., Cahn-Weiner D. A., Stoessl A. J., Olanow C. W. & Bartus R. T. (20080801). Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. : The Lancet. Neurology.

Chicago

Marks William J, Ostrem Jill L, Verhagen Leonard, Starr Philip A, Larson Paul S, Bakay Roy Ae, Taylor Robin, Cahn-Weiner Deborah A, Stoessl A Jon, Olanow C Warren and Bartus Raymond T. 20080801. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. : The Lancet. Neurology.

Harvard

Marks W. J., Ostrem J. L., Verhagen L., Starr P. A., Larson P. S., Bakay R. A., Taylor R., Cahn-Weiner D. A., Stoessl A. J., Olanow C. W. and Bartus R. T. (20080801). Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. : The Lancet. Neurology.

MLA

Marks William J, Ostrem Jill L, Verhagen Leonard, Starr Philip A, Larson Paul S, Bakay Roy Ae, Taylor Robin, Cahn-Weiner Deborah A, Stoessl A Jon, Olanow C Warren and Bartus Raymond T. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. : The Lancet. Neurology. 20080801.